Evolocumab significantly reduces risk of cardiovascular events

Evolocumab, one of the new targeted PCSK9 inhibitor drugs that has been shown to dramatically lower levels of low-density lipoprotein (LDL), or “bad” cholesterol, also significantly lowers the risk of cardiovascular events in patients with existing heart or vascular disease already on statin therapy, according to new research.

Leave a Reply

Your email address will not be published. Required fields are marked *